In a phase 2 trial of patients with untreated, recurrent and progressive brain metastases treated with an anti-programmed cell death protein 1 inhibitor, the overall intracranial benefit rate was 42.1%, which met the prespecified primary endpoint.
- Priscilla K. Brastianos
- Albert E. Kim
- Ryan J. Sullivan
